Background: Non-influenza respiratory viruses are a major cause of morbidity and mortality. Susceptibility to certain viral infections could be a marker of pulmonary inflammatory processes, and, thereby, an indication to enhance the treatment of chronic illness. Our study objective is to clinically correlate the epidemiology, severity, and outcomes associated with all non-influenza respiratory viruses at our institution (detected by polymerase chain reaction (PCR)) and to compare the data with that of influenza viruses at our institution.
Methods: We performed a retrospective cohort study of adult patients admitted to Beaumont Hospitals from January 1st, 2014 to December 31st, 2014 who had a positive PCR result.
Results: We identified 1347 patients who met our inclusion criteria. Of these patients, 100 were randomly chosen based on a computer-generated randomizer. Study patients median age = 74.5 years. 13 patients were positive for influenza virus and had symptoms > 48 hours prior to admission; of these patients, 10 were treated with oseltamivir. At our center, the greatest incidence of respiratory viral infections was in November, during which Influenza A – H3 was the most prevalent (Figure 1). Human rhinovirus was the most prevalent respiratory virus overall and had the greatest incidence in September. The most common symptom was cough for all viruses (Figure 2). The average time of onset before admission was greatest with Human Metapneumovirus (10.67 days) and least with Parainfluenza Type 2 (1 day) (Figure 3). Interestingly, respiratory viral testing was checked late after admission for patients who were found to be positive for Rhinovirus (3.46 days) as compared to Influenza H1N1 (1 hour). ICU admission and mortality were not significantly different between virus groups.
Conclusion: Our study did not show significant difference in mortality between different respiratory viruses. Early identification of a viral pathogen, however, is crucial in isolating infected patients in health care settings to prevent transmission of disease. Interestingly, our study showed that despite symptom onset greater than 48 hours prior to admission, most patients who were positive for influenza were still treated with oseltamivir.
Figure 1 – Monthly Summary of each respiratory virus
L. Qu, None
B. Boyanton, None
C. Carpenter, None